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Genome-wide profiling of humoral 
immunity and pathogen genes 
under selection identifies immune 
evasion tactics of Chlamydia 
trachomatis during ocular infection
Harry Pickering1, Andy Teng2, Nkoyo Faal3, Hassan Joof3, Pateh Makalo3, Eunice Cassama4, 
Meno Nabicassa4, Anna R. Last1, Sarah E. Burr1,3, Sarah L. Rowland-Jones3, Nicholas 
R. Thomson5,6, Chrissy h. Roberts  1, David C. W. Mabey1, Robin L. Bailey1, Richard D. 
Hayward7, Luis M. de la Maza8 & Martin J. Holland  1,3
The frequency and duration of Chlamydia trachomatis (Ct) ocular infections decrease with age, 
suggesting development of partial immunity. However, there is a lack of clear correlates of immunity 
to Ct infection in humans. We screened sera from a cohort of Gambian children followed for six-months 
against a Ct-proteome microarray. At genome sequence level, we detected signatures of selection 
from a population of ocular Ct isolates from Guinea-Bissau. Together these approaches allowed us to 
highlight the focus of humoral responses and hypothesise new modes of pathogen immune evasion. 
Children who were susceptible to frequent and/or prolonged Ct infection had a less focussed antibody 
response, including preferential recognition of forty-two antigens. There was evidence of positive 
and purifying selection across the genome, but little balancing selection. In contrast, most antigens 
that were associated with susceptibility were under neutral selection. These data suggest an evasion 
strategy in which Ct presents a large panel of irrelevant antigens to the immune system to block or 
misdirect protective responses. Development of a focused immune response, possibly induced through 
vaccination, may be an effective strategy to promote protection to Ct infection.
Ocular infection with Chlamydia trachomatis (Ct) causes trachoma, the leading infectious cause of blindness1. 
Both ocular Ct infection and active disease prevalence decline from their peaks in pre-school children (one to 
four years old) to older children (five to fourteen years old) and from this group to adults (fifteen years or older)2, 3. 
This suggests that partial Ct immunity develops with increasing age in endemic communities, notwithstanding 
reduced exposure to Ct with increasing age4.
Conjunctival Ct infection induces a strong pro-inflammatory response marked by production of cytokines5, 
recruitment of neutrophils, macrophages and NK-cells6, 7. Induction and proliferation of CD4+ T-cells and pro-
duction of interferon-gamma (IFNγ) have been implicated in successful resolution of infection in animal models 
and human infections8–11. Ocular Ct infection additionally induces local and systemic antibodies12. Neutralising 
antibodies against Ct have been demonstrated in animal models13 and in vitro14. Paradoxically in a longitudinal 
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study from The Gambia, higher IgG responses against the immunodominant major outer membrane protein 
(MOMP) were associated with higher rates of infection and higher titres increased the associated risk15. Ocular 
Ct infection clearly induces a strong humoral immune response, but its role in protection or pathology in humans 
in vivo remains unclear.
Screening whole-proteome arrays has become an effective method to describe the complete profile of antibody 
responses in infection and disease16. Studies utilising these proteome arrays have highlighted some common 
themes in humoral immune targets of human pathogens including functions in protein binding and catalytic 
activities, early or late expression in the developmental cycle and membrane localisation17.
Genome-wide analyses of the type or mechanisms of selection have been conducted on a number of human path-
ogens and identified known and novel targets that were under immune selective pressures. Studies in many human 
pathogens, including P. falciparum18, 19, Helicobacter pylori20, Staphylococcus aureus21 and Streptococcus pneumonia22, 
have highlighted cellular and humoral immune targets, cell surface proteins and known host-interactors as over-
represented in genes under both balancing (selection and maintenance of multiple alleles) and positive selection 
(selection of advantageous alleles).
Until recently, the number of sequenced Ct genomes has been low and they have been derived from speci-
mens that were collected from ecologically disparate sites over a timespan >50 years (Harris et al.23). A study 
by Thomson et al.24 utilizing 3 genomes, more recent studies by Joseph et al.25, 26 utilising 12 and 32 genomes 
respectively followed by Borges et al.27 (n = 59 genomes), identified positive selection in known host-interactors 
that were either surface-exposed or secreted into the host cytosol. Most recently, Hadfield et al. analysed 563 
Ct genomes28. Similar to the prior studies, they focussed on global diversity of the species and its evolutionary 
history, rather than within-population dynamics. In trachoma, previous studies have focused on the popula-
tion genetics of ompA, which encodes the immunodominant MOMP. Two populations of Ct sequences from 
trachoma-endemic communities in The Gambia29 and Tanzania30 suggested ompA was under purifying (selection 
against deleterious alleles) and positive selection; similar variation in selection pressure has been found in uro-
genital Ct sequences31. A lack of balancing selection in this immunodominant antigen, which is a target of neu-
tralising antibodies, is in contrast to other pathogens and highlights the need for further population-based studies 
of Ct-genes under selection to better understand the interactions between Ct and the host immune system.
We used sera, collected from Gambian children at the baseline point of a six-month longitudinal cohort, to 
screen a protein microarray of 894 genomic ORFs from serovar D Ct32. The complete profile of responses for each 
sample was determined and used to investigate the differential recognition of individual antigens and estimate 
the diversity and evenness of the antibody response associated with the frequency and duration of Ct infection. 
A population of 126 complete genome sequences of ocular Ct samples obtained from discrete communities of 
four Bijagos Islands (Guinea-Bissau) collected in a single survey33, 34 was used in tests of population genetic selec-
tion. Genome-wide evidence of selection and genome-wide screening of the antibody response in the context of 
susceptibility to ocular infection observed over a 6-month period were overlaid. This enabled us to identify new 
targets of humoral immunity and we uncovered two complementary immune evasion tactics that may support Ct 
survival and promote recurrent infection.
Results
Immunity defined by susceptibility to infection. After normalisation and filtering to remove infre-
quently recognised antigens, responses of 90 individuals covering 441 antigens were included in the analysis. 
Individuals were divided into those resistant or susceptible based on observed median duration of infections over 
the six-month study period (Supplementary Figure 1). The study-wide median duration of infection was 2 weeks 
(or one visit). Those with no infections or short duration infections were combined (≤2 weeks; resistant) and 
compared to those with long duration infections (>2 weeks; susceptible). The demographic similarity of resistant 
and susceptible individuals indicated that history of ocular Ct exposure was similar (Table 1).
Resistant Susceptible p-value
Number 60 30 NA
Age in years 
(95% CI)
9.00 (2.00–
11.53) 8.00 (1.73–12.00) 0.413
Female (n [%]) 24 (40.00) 13 (43.33) 0.762
Village (n [%])
<0.001
−1 7 (11.67) 19 (63.33)
−2 2 (3.33) 0 (0.00)
−4 5 (8.33) 1 (3.33)
−6 11 (18.33) 3 (10.00)
−7 27 (45.00) 7 (23.33)
−8 8 (13.33) 0 (0.00)
Table 1. Age, gender and village membership in resistant and susceptible groups screened on the micro-array. 
Association with resistance or susceptibility to infection was determined using a generalised linear model. For age, 
numbers in parentheses are the 95% confidence intervals around the median. For gender and village, numbers in 
parentheses are the percentage. No individuals from villages 3 and 9 were screened on the micro-array.
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Diversity of the antibody response and infection susceptibility. The complete profile of antibody 
responses in resistant and susceptible individuals was used to investigate differences in diversity or evenness of 
anti-Ct responses. Breadth, defined as the number of antigens recognised by an individual, was higher in suscep-
tible individuals but this was not significant (p = 0.088) (Fig. 1A). Diversity indices, which incorporate breadth 
and the relative strength of responses against an antigen, were higher in susceptible individuals. This reached 
significance for Shannon’s (p = 0.024) but not Simpson’s diversity indices (p = 0.080) (Fig. 1B and C). Together 
these indicate broader, less focussed antibody responses in susceptible individuals.
Individual antibody responses were associated with increased susceptibility. Association 
between responses to individual antigens and infection frequency and duration was determined using a gen-
eralised linear model adjusting for other major risk factors (age, gender and village of residence). Forty-two 
antigens were identified as targets of differential antibody responses between resistant and susceptible individuals 
(p ≤ 0.05) (Table 2). Higher responses to each of these antigens was associated with susceptibility to infection.
To examine when and how these antigens might be targeted by the host immune response during the Ct devel-
opmental cycle, their expression stage from Belland et al.35 and predicted localisation from three computational 
tools (loctree3, Cello and pSORTB) were compared between the 42 differentially recognised antigens and the 441 
antigens (Supplementary Table 1). A χ2 test was used to quantify over-representation or under-representation 
of expression stage or predicted localisations in the differentially recognised antigens, compared to all 441 anti-
gens. Very early (1 hour post infection [HPI]) and very late (24–36 HPI) expressed genes were significantly 
over-represented (p = 0.007). Secreted, inner membrane and periplasmic proteins were weakly over-represented 
in these antigens (p = 0.056). Experimentally defined localisation of these antigens showed mixed agreement with 
software predictions, a number of those known to be secreted or reside in the outer membrane were incorrectly 
classified as remaining inside the inclusion. There was less individually-determined data available for expression 
Figure 1. Breadth and diversity of responses in resistant and susceptible individuals. Notched boxplots of 
breadth/diversity of responses (x-axis) in resistant and susceptible individuals (y-axis). (A) Breadth measured as 
the number positive responses within individuals (p = 0.088). Diversity measured using (B) Shannon’s diversity 
index (p = 0.024) and (C) Simpson’s diversity index (p = 0.080). Median (red lines) and notches were calculated 
as the median +/− 1.57 × IQR/sqrt of n, where IQR is the interquartile range and n is the number of samples. 
The IQR times 1.5 was added to the 75th percentile and subtracted from the 25th percentile to determine the 
whiskers. Dots are outliers.
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stage, although some antigens predicted to peak at 40 HPI have been shown since to peak 1–6 HPI. These disa-
greements, in classification of expression stage and localisation, strengthen the over-representation of antigens 
expressed early or late and localised to interact directly with the host.
Genome-wide evidence of purifying and positive selection. In general, pathogen immunogenic 
proteins are under natural selection, due to their impact on pathogen survival and transmission. To validate 
identified immune targets and identify further targets, sequence data from 126 ocular Ct samples from the 
Bjiagos Islands, Guinea-Bissau was examined for evidence of departure from neutral selection. These samples 
were collected and sequenced as described elsewhere33, 34, details in Supplementary Methods. Currently, no Ct 
whole-genome sequences are available from the villages included in this study. To determine the relevance of 
evidence of selection in samples from the Bijagos Islands, they were compared with five historical isolates from 
Antigen p-value p* t SE(t) OR* 95% CI* AUC
CT545 0.001  < 0.001 8.38 2.63 9.05 2.57–39.71 0.78
CT118 0.003 0.002 6.40 2.18 8.18 2.19–37.48 0.78
CT123 0.004 0.001 6.43 2.21 8.7 2.23–43.16 0.76
CT541 0.006 0.004 6.09 2.21 6.74 1.85–28.71 0.78
CT664 0.009 0.008 5.76 2.20 6.36 1.71–28.27 0.80
CT119 0.009 0.007 5.19 1.98 4.35 1.51–14.00 0.76
CT381 0.010 0.009 5.03 1.96 4.56 1.48–15.49 0.76
CT584 0.012 0.010 6.90 2.75 6.3 1.62–29.64 0.76
CT284 0.012 0.009 6.34 2.53 4.83 1.51–18.22 0.74
CT502 0.014 0.012 6.46 2.62 5 1.50–19.93 0.80
CT051 0.017 0.015 5.06 2.11 5.44 1.47–24.26 0.74
CT592 0.019 0.018 4.14 1.77 3.6 1.28–11.23 0.75
CT073 0.020 0.017 6.01 2.58 6.91 1.47–39.52 0.77
CT078 0.020 0.018 6.07 2.61 4.88 1.38–20.58 0.74
CT023 0.022 0.019 6.60 2.88 7.61 1.56–51.76 0.77
CT223 0.022 0.020 5.93 2.59 4.11 1.31–15.14 0.76
CT795 0.024 0.018 3.91 1.73 3.67 1.23–11.93 0.76
CT875 0.028 0.030 5.14 2.34 4.21 1.22–16.47 0.73
CT181 0.030 0.024 4.32 1.99 4.05 1.20–15.42 0.75
CT694 0.031 0.031 3.91 1.81 3.68 1.17–12.78 0.74
CT021 0.034 0.033 5.45 2.57 4.72 1.19–21.77 0.77
CT813 0.035 0.033 3.50 1.66 3.13 1.12–9.57 0.75
CT841 0.036 0.035 3.77 1.80 3.15 1.12–9.78 0.74
CT017 0.036 0.039 3.77 1.80 4.37 1.16–18.92 0.75
CT142 0.036 0.037 4.24 2.03 3.41 1.12–11.48 0.74
CT764 0.037 0.034 5.74 2.75 4.5 1.18–20.92 0.78
CT728 0.039 0.040 4.86 2.35 3.97 1.14–16.23 0.78
CT228 0.039 0.037 5.54 2.69 4.34 1.16–19.64 0.74
CT703 0.040 0.042 4.82 2.34 5.76 1.20–34.90 0.74
CT494 0.040 0.037 5.63 2.74 5.62 1.19–32.96 0.76
CT106 0.041 0.039 5.87 2.87 3.45 1.11–12.30 0.76
CT097 0.041 0.040 5.50 2.70 3.6 1.10–13.26 0.75
CT316 0.043 0.049 6.00 2.96 3.66 1.10–14.02 0.75
CT579 0.044 0.041 3.73 1.85 3.55 1.09–13.26 0.77
CT168 0.044 0.044 6.32 3.14 5.37 1.19–32.48 0.76
CT089 0.044 0.045 4.54 2.26 3.34 1.07–11.61 0.75
CT237 0.045 0.043 5.79 2.88 4.53 1.13–22.39 0.75
CT806 0.046 0.046 4.89 2.45 3.49 1.08–12.84 0.76
CT668 0.048 0.049 5.68 2.87 3.45 1.07–12.91 0.77
CT642 0.048 0.047 5.80 2.93 3.39 1.08–12.52 0.76
CT695 0.049 0.053 3.73 1.90 3.44 1.06–12.84 0.75
CT570 0.050 0.049 5.92 3.02 4.29 1.08–20.48 0.76
Table 2. Forty-two differentially recognised antigens between resistant and susceptible individuals. Univariate 
associations were determined using a generalised linear model. Variables were resampled 10,000 times and 
remodelled to determine permuted p-values (P*). Odds ratios (OR) and confidence intervals (CI) were 
calculated for an increase of half the range per antigen, rather than one unit. The predictive value of the 
univariate generalised linear models was calculated and presented as area under the curve (AUC).
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The Gambia (Supplementary Figure 2). The Bijagos Islands samples were separated from each other by 1–1119 
SNPs, the Gambian samples were separated by 161–1704 SNPs and the two populations of samples were separated 
by 487–1019 SNPs. As expected, based on previous Ct sequences, this suggests the geographically-distinct pop-
ulations are close genetic relations, supporting the use of the Bijagos Islands samples in predicting genes under 
selection within those circulating in The Gambia. Therefore we tested for evidence of departure from neutrality 
using a number of tests including Tajima’s D, Fay and Wu’s H, and the integrated haplotype score.
Tajima’s D can distinguish between directional selection (positive or purifying selection [D ≤ −1.8]) and bal-
ancing selection (D ≥ 2.044), by comparing the levels of low and medium frequency alleles36. Fay and Wu’s H can 
distinguish between balancing/positive selection and balancing/purifying selection, by comparing the levels of 
low and high frequency alleles. Balancing (D ≥ 2.044 and 0.72 ≤ H ≤ −3.85), positive (D ≤ −1.8 and H ≤ −3.85) 
and purifying selection (D ≤ −1.8 and H ≥ 0.72) can be differentiated, by combining D- and H-values.
Nineteen genes with evidence of selection by Tajima’s D were supported by Fay and Wu’s H. Ten of these genes 
had evidence of positive selection and 9 genes had evidence of purifying selection (Fig. 2A and Table 3 [‘Windows 
under selection’ = 0]). D- and H-values were then determined using a 42 base pair sliding window analysis, this 
window equates to the most frequent length of an antibody epitope (16 amino acids). Seventy-six windows across 
12 genes had evidence of positive selection and 61 windows across 8 genes had evidence of purifying selection 
(Fig. 2B and Table 3 [‘Windows under selection’ >0]). Evidence of natural selection acting on/within these genes 
suggests they may influence Ct survival and transmission.
Integrated haplotype scores identify three genomic regions under positive selection. 
Identification of positive selection by Tajima’s D and Fay and Wu’s H is most powerful when an allele is close to 
fixation (only one allele at a given site). A genome-wide scan was performed to calculate integrated haplotype 
scores (iHS) for SNPs, to identify genes and regions under positive selection that have not yet reached fixation.
The median iHS score was 0.66 (95% CI 0.03–2.18), 20 SNPs in the top 1% of the genome-wide distribution 
of iHS (Fig. 3). The top 1% of SNPs highlighted three loci, which showed evidence of recent positive selection; 
Figure 2. Correlation between Tajima’s D and Fay and Wu’s H. Genome-wide correlation of D and H values 
at (A) gene-level and (B) epitope-level (sliding windows of 42 bp). Values significantly different from zero 
are indicated for each measure (dashed red lines). Genes with evidence of positive (blue), purifying (red) and 
balancing selection (green) are highlighted.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 9634  | DOI:10.1038/s41598-017-09193-2
CT048-CT074, CT154-CT155 and CT456-CT625. These loci include a region covering tarP and pmp family 
members and a region within the Ct plasticity zone.
Ct genes important for Ct survival and pathogenesis were the focus of natural selection. In 
this population of ocular Ct samples, 48 genes were identified with evidence of selection by either a combination 
of Tajima’s D and Fay and Wu’s H, at the gene or epitope level, or by iHS. Expression stage of these genes and 
localisation of the translated proteins was examined to discover common patterns in genes with evidence of 
selection (Supplementary Table 2). Secreted and outer membrane proteins were significantly over-represented in 
these targets (p = 0.004), as were genes with peak expression levels very early or very late in the developmental 
cycle (p = 0.0005). Expression at these pivotal stages of infection and extra-inclusion localisations suggests these 
genes are important factors in Ct survival and pathogenesis. Similar to the 42 antigens identified in this study, 
comparison of the array-determined expression stage and predicted localisation to more recent experiments 
supported these findings.
Variable evidence of selection acting on genes associated with infection frequency and dura-
tion. Evidence of selection is a common marker of pathogen immunogenic proteins due to their interactions 
with the host and impact on pathogen survival and transmission. Therefore, we examined the 42 antigens asso-
ciated with susceptibility to infection for evidence of selection, as one means of validation as important immune 
targets (Fig. 4 and Supplementary Table 3).
Four of 42 targets associated with susceptibility to infection had gene-level evidence of selection by Tajima’s D, 
supported by Fay and Wu’s H. CT694 and CT695, had evidence of positive selection at the epitope level supported 
by D and H values. CT545 and CT806 had evidence of purifying selection at the epitope level.
Ten genes were within regions under positive selection by iHS. One target, susceptibility-associated CT228, 
contained a SNP under positive selection by iHS.
The majority of the antigens associated with susceptibility had no evidence of selection in this population, 










CT033 recD_1 15 −5.41 −2.29 0 Positive
CT046 hctB 33 1.00 −1.33 2 Purifying
CT082 12 −9.32 −2.12 1 Positive
CT105 45 2.40 −2.27 13 Purifying
CT147 32 −12.23 −1.33 24 Positive
CT159 19 −3.23 −2.28 4 Positive
CT223 IPAM 15 0.91 −1.87 0 Purifying
CT249 5 −5.67 −1.78 1 Positive
CT288 12 −12.55 −1.88 0 Positive
CT359 8 −5.55 −1.83 1 Positive
CT386 7 −7.75 −2.07 0 Positive
CT394 hrcA 15 0.73 −2.01 0 Purifying
CT414 pmpC 41 −2.88 −1.52 16 Purifying
CT442 crpA 28 −0.86 −2.52 17 Purifying
CT456 tarP 32 −6.84 −1.62 8 Positive
CT539 trxA 4 −3.87 −1.76 2 Positive
CT621 16 0.90 −1.93 0 Purifying
CT622 47 −48.13 −1.66 4 Positive
CT624 mviN 17 0.91 −2.00 0 Purifying
CT636 greA 15 0.73 −2.07 0 Purifying
CT641 ygeD 42 1.13 −2.38 0 Purifying
CT651 51 0.32 −2.63 0 Purifying
CT674 yscC 51 1.30 −2.85 0 Purifying
CT681 ompA 25 −0.46 −2.20 13 Purifying
CT686 sufD 20 −19.50 −1.78 21 Positive
CT688 parB 7 −5.71 −1.96 3 Positive
CT694 14 −6.89 −2.21 6 Positive
CT868 Dub1 19 −9.36 −2.48 0 Positive
CT872 pmpH 68 1.99 −2.85 0 Purifying
Table 3. Genes under selection identified by Tajima’s D and Fay and Wu’s H. Number of SNPs per gene and the 
gene-level Tajima’s D and Fay and Wu’s H values are indicated. The number of sliding windows with significant 
evidence of selection by both Fay and Wu’s H and Tajima’s D are indicated (‘Windows under selection’). Type of 
selection is indicated.
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Discussion
There is considerable evidence from animal models suggesting antibody responses are necessary for long-term 
protection and immunity from chlamydial infection37–39. In mice, the breadth of the antibody response is higher 
in strains that are more susceptible to chlamydial infection and associated pathology40–42. Furthermore, in 
non-human primates, partial immunity to ocular infection was consistent with development of a focussed anti-
body recall response43.
Previous work on the Gambian six-month longitudinal cohort utilised in this study focussed on systemic 
and local cell-mediated immune responses44, 45. To gain a more complete picture of the immune responses 
underlying differential outcomes, we screened serum samples against a Ct protein microarray to examine the 
relationship between individual serological immune responses and the acquisition and resolution of ocular Ct 
infection. Antibody responses were more focused in children who were able to resolve infection, while height-
ened responses to 42 antigens were associated with susceptibility to infection and longer durations of infection.
Tests for selection identified a number of genes and regions of the Ct genome under purifying and posi-
tive selection, using 126 ocular samples collected from the Bijagos Islands (Guinea-Bissau). These regions were 
focused in immunogenic proteins and those that interact directly with the host. This result was further strength-
ened by using experimentally derived expression stage and localisation of individually investigated genes, as 
opposed to array-based profiling of expression and bioinformatics prediction of localisation. Evidence for selec-
tion within the potential immune targets identified from the proteome array analysis was variable, 5/42 targets 
had significant evidence of selection.
Genes important in host-pathogen interactions are under natural selection. Most frequently, selection is 
observed in pathogen immune targets, where balancing and/or positive selection can aid immune evasion46. 
We found evidence of selection in Ct genes that code for known or putative immune targets or virulence factors, 
similar to previously described Ct genomics studies24–27. Genes coding for proteins involved in cell entry, cell exit 
and intracellular interactions via the inclusion membrane encompassed the majority of genes under selection. 
Additionally, 17 of 48 genes with evidence of selection have no known function, suggesting these genes may be 
important for Ct survival and transmission. Genome-wide scans for evidence of selection therefore have the abil-
ity to highlight important, previously uncharacterized genes.
Seventeen of the genes under selection are known to be immunogenic; this supports immune-recognition as 
a key driving factor of selection within this population of ocular Ct samples. However, there was limited evidence 
of balancing selection, a common mechanism of immune evasion employed by human pathogens18, 21, 47, 48. This 
method of immune evasion relies on cyclical presentation of alternative forms of immunodominant, primarily 
surface-exposed, antigens to the host immune system to avoid recognition and clearance.
Figure 3. Evidence of positive selection using the integrated haplotype score. Genes in the top 1% of values 
(dashed red line) had the strongest evidence of positive selection. Regions (blue lines) and individual SNPs (blue 
shading) under positive selection are indicated.
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Typically, in trachoma endemic communities where immunity develops slowly, Ct is able to reinfect indi-
viduals within the same households or village. The lack of protective antibodies, combined with the absence of 
balancing selection, suggests that Ct employs a different strategy for immune evasion. The results suggest two 
potential routes for immune evasion, a) blocking and/or invasion-enhancing antibodies against surface antigens 
or b) masking of protective humoral immune responses through heightened responses against a large number of 
immunogenic but non-protective antigens.
Blocking antibodies are induced by surface antigens of P. falciparum49, Candida albicans and Neisseria gonor-
rhoeae and can inhibit protective responses50, 51. Antibody-dependent enhancement is a well-described process 
Figure 4. Evidence of selection in antibody targets associated with susceptibility to infection. Evidence of 
selection was determined at the gene-level (A) and the epitope-level (B) by Tajima’s D and Fay and Wu’s H. 
Evidence of positive selection on SNPs and larger genomic regions was independently determined by iHS (C). 
Association with susceptibility to infection is indicated (red). Thresholds for genes considered under selection, 
values significantly different from zero, is indicated for each measure (dashed red lines). Genes or SNPs (C) with 
evidence of positive (blue), purifying (red) and balancing selection (green) are highlighted.
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in viral infections52, 53, involving cross-linking of host-cell surface receptors by virus-antibody complexes leading 
to enhanced infectivity. Similar observations in P. vivax54 suggest this mechanism may be more widely utilized 
by pathogens.
Through Ct-protein array screening of serum from children resistant or susceptible to frequent and/or pro-
longed Ct infection, we identified three susceptibility associated surface antigens CT017 (Ctad1), CT541 (MIP) 
and CT579. Antibodies generated against non-protective surface antigens provide a survival advantage for Ct and 
such mutations would be expected to be under purifying selection. There was no clear evidence of selection in 
these antigens. However, three of four outer membrane proteins (ompA [MOMP], pmpC and pmpH) with strong 
evidence of selection were under purifying selection, suggesting these antigens are targets of blocking and/or 
invasion-enhancing antibodies. In support of this, MOMP can induce blocking55 and invasion-enhancing anti-
bodies14, 56 in vitro and in mouse models.
The majority of the 42 susceptibility associated antigens were not localised to the EB surface, therefore their 
role in Ct infection and disease cannot be explained by a hypothesis that solely involves non-protective surface 
antigens. The breadth of the antibody response shows that a high number of Ct antigens are accessible to the host 
immune system, likely through release of Ct proteins as a result of inclusion/host cell lysis or recently described 
chlamydial extrusions57, 58. Antibody responses against the majority of Ct proteins are not protective, leading to 
a hypothesis that heightened responses to a large number of immunogenic but not protective antigens masks 
protective humoral immune responses.
A diverse antibody profile would provide an advantage for the bacteria therefore targeted genes would be 
expected to be under purifying selection, however the number of antigens targeted and their inherently random 
nature implies no one gene would show strong evidence of selection. In support of evasion by decoy, 37/42 of the 
antigens identified as susceptibility-associated had no strong evidence of selection. Of the five under selection, 
two had evidence of purifying selection (CT545 and CT806). The remaining three were under positive selection 
(CT228, CT694 and CT695), however they are known virulence factors59–63, therefore immune evasion may not 
be the only driving force of selection.
Ideally, samples from the Gambian villages utilised in this study would have been screened for evidence of selection, 
however whole-genome sequences are currently unavailable. The phylogeny of the Bijagos Islands samples and the pre-
viously published Gambian samples, suggests they are closely related. This relatedness and the similar community-level 
endemicity of active trachoma (Gambian cohort 21.5% and Bijagos Islands 22% [one to nine year olds]) and ocular 
Ct infection (Gambian cohort 9.9% and Bijagos Islands 25% [one to nine year olds]), support the assertion that the 
genes under selection may be shared between these geographically-separated Ct populations. Additionally, evidence of 
diversity within the Bijagos Islands samples and historical Gambian samples, suggests observed differences in infection 
frequency and duration between villages are not due to the presence of a single dominant Ct clone.
These data demonstrate the value of genomic information in the identification of immune targets and virulence 
factors, particularly in combination with proteome-wide antibody responses. Less focussed antibody responses in sus-
ceptible individuals and evidence of purifying selection in Ct surface antigens, support an evasion strategy in which 
Ct presents a number of non-protective, irrelevant antigens to the immune system to block or misdirect protective 
responses. These results will allow targeted development of vaccine candidates and may explain the observed success of 
single and multi-antigen vaccines against Ct, as they would promote a focussed, protective humoral immune response. 
In summary, our data support the importance of antibody responses in human immunity to Ct infection.
Methods
Ethics statement. The Gambian longitudinal cohort was conducted in accordance with the Declaration of 
Helsinki. The study and its procedures were approved by the Gambia Government/Medical Research Council 
The Gambia Unit Joint Ethics Committee and by the Ethics Committee of the London School of Hygiene and 
Tropical Medicine (LSHTM). Verbal consent was obtained from community leaders. Written informed consent 
was obtained from all study participants’ guardians on their behalf. A signature or thumbprint is considered an 
appropriate record of consent in this setting by the above ethical bodies.
The Bissau-Guinean cross-sectional survey was conducted in accordance with the Declaration of Helsinki. 
The study and its procedures were approved by the Comitê Nacional de Ética e Saúde (Guinea-Bissau) and the 
LSHTM Ethics Committee. Verbal consent was obtained from community leaders. Written informed consent was 
obtained from all study participants or their guardians on their behalf if participants were children. A signature or 
thumbprint is considered an appropriate record of consent in this setting by the above ethical bodies.
Clinical cohort study and participants. A six-month longitudinal study was previously conducted and 
recruited 345 children, aged four to fifteen years old, from nine villages in The Gambia11. Villages were selected 
following initial trachoma rapid assessment screening that found clinical signs of active trachoma in 20% of 
school age children. At baseline and at each fortnightly visit for six-months, children were examined for clinical 
signs of active trachoma. Trachoma was graded according to the simplified WHO grading system64. Two conjunc-
tival swabs were collected in duplicate to test for Ct infection and tear fluid was collected for mucosal cytokine 
and antibody assays. Venous blood samples were collected at baseline and cessation of the study, 186 samples were 
collected. Villages 3 and 9 declined to give venous blood samples and could not be included in this study.
Chlamydia trachomatis antigen microarrays. Ninety sera from baseline and 33 sera from the end of 
the study were screened against a previously published protein microarray covering 894 genomic open reading 
frames (ORFs) from serovar D Ct32. Briefly, 894 ORFs were cloned into the pXT7 expression vector, proteins were 
expressed and printed on glass slides. After blocking, the arrays were probed with diluted sera, bound antibody 
was detected using a biotin-conjugated anti-human antibody followed by a streptavidin-conjugated secondary 
antibody.
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Proteome microarray normalisation, filtering and clustering. The raw signal intensity data 
(Supplementary Table 4) from the protein micro-array was transformed by inverse hyperbolic sine transforma-
tion and normalised by mean-centring. To filter out infrequently recognised antigens, post-normalisation, the 
global median of the data was calculated and individual antigens whose median was lower than the global median 
were excluded from further analysis.
Different methods to identify positive-negative breakpoints in the distribution of the data were tested. 
Silhouette width was used to quantify the best method. Cluster separation per antigen was derived from the aver-
age silhouette width. To classify positive responses, two clusters were identified using the method that had the 
highest average silhouette width for each antigen.
Diversity metrics. Breadth of response was defined as the number of antigens to which each individual had 
a positive response. Diversity was calculated using Shannon’s entropy (H) and Simpson’s diversity index (D).
Statistical analyses. Intensity of responses was compared using a generalised linear model (glm) and the 
number of positive responses using Fisher’s exact test. For the glm, 10,000 permutations of the outcome variable 
were performed to generate an adjusted p-value. Adjusted odds ratios (OD*) and adjusted confidence intervals 
(CI*) were calculated as the unadjusted OR/CI exponentiated by half the range for a given antigen.
Chlamydia trachomatis population genetic metrics. As part of a cross-sectional population-based 
survey in trachoma-endemic communities on the Bijagós Archipelago of Guinea-Bissau, upper tarsal conjuncti-
val swabs were taken33. Whole-genome sequence data (Supplementary Table 5) was obtained from 126 Ct-positive 
swabs using SureSelect enrichment and Illumina paired-end DNA sequencing technology and assembled using 
the A/Har13 as reference genome. Aligned multi-fasta files for each gene were used as input for Variscan-2.0.365 
to calculate Tajima’s D and Fay and Wu’s H. Integrated haplotype scores (iHS) were calculated using the rehh 
package in R. Missing base-calls were imputed using a genetic-distance based method.
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